PFKFB3-mediated endothelial glycolysis promotes pulmonary hypertension

Yapeng Cao(Peking University), Xiaoyu Zhang(Peking University), Lina Wang(Peking University), Qiuhua Yang(Peking University), Qian Ma(Peking University), Jiean Xu(Peking University), Jingjing Wang(Peking University), László Kovács(Peking University), Ramon J. Ayon(University of Arizona), Zhiping Liu(Peking University), Min Zhang(Peking University), Yaqi Zhou(Peking University), Xianqiu Zeng(Peking University), Yiming Xu(Augusta University), Yong Wang(Augusta University), David Fulton(Augusta University), Neal L. Weintraub(Augusta University), Rudolf Lucas(Augusta University), Zheng Dong(Augusta University), Jason X.‐J. Yuan(University of Arizona), Jennifer C. Sullivan(Augusta University), Louise Meadows(Augusta University), Scott A. Barman(Augusta University), Chaodong Wu(Texas A&M University), Junmin Quan(Peking University), Mei Hong(Peking University), Yunchao Su(Augusta University), Yuqing Huo(Augusta University)
Proceedings of the National Academy of Sciences
June 18, 2019
Cited by 220Open Access
Full Text

Abstract

Significance Lung endothelial cells express high levels of glucose metabolic enzymes, such as PFKFB3, and consequently produce large amounts of glucose metabolites. These metabolites are able to stabilize the cell signaling molecule HIF2A, similar to that which occurs under hypoxic conditions. This stabilization of HIF2A by glucose metabolites in lung endothelial cells stimulates production of growth and inflammatory factors, thereby enhancing proliferation and inflammation of the pulmonary vessels and exacerbating pulmonary hypertension (PH). In this study, blockade of endothelial PFKFB3 inhibits PH development in rodent models, suggesting that targeting glucose metabolic enzymes is a promising strategy for the treatment of PH.


Related Papers

No related papers found

Powered by citation graph analysis